强生(JNJ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

JNJ 强生

盘前交易 10-02 08:33:37 EDT

155.75

-1.13

-0.72%

盘前155.44

-0.31-0.20%

08:30 EDT

最高157.60	最低155.35	成交量768.06万
今开157.37	昨收156.88	日振幅1.43%
总市值3,750亿	流通市值3,745亿	总股本24.08亿
成交额11.97亿	换手率0.32%	流通股本24.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"JNJ","market":"US","secType":"STK","nameCN":"强生","latestPrice":155.75,"timestamp":1696017600000,"preClose":156.88,"halted":0,"volume":7680611,"hourTrading":{"tag":"盘前","latestPrice":155.435,"preClose":155.75,"latestTime":"08:30 EDT","volume":33965,"amount":5290068.449700001,"timestamp":1696249816352},"delay":0,"floatShares":2404458774,"shares":2407969594,"eps":4.934181,"marketStatus":"盘前交易","marketStatusCode":1,"change":-1.13,"latestTime":"10-02 08:33:37 EDT","open":157.37,"high":157.6,"low":155.35,"amount":1196790732.25503,"amplitude":0.014342,"askPrice":155.55,"askSize":100,"bidPrice":155.42,"bidSize":1,"shortable":3,"etf":0,"ttmEps":4.934181,"exchange":"NYSE","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1696253400000},"adr":0,"listingDate":-797371200000,"adjPreClose":155.75,"adrRate":0,"dividendRate":0.029406,"preHourTrading":{"tag":"盘前","latestPrice":155.435,"preClose":155.75,"latestTime":"08:30 EDT","volume":33965,"amount":5290068.449700001,"timestamp":1696249816352},"postHourTrading":{"tag":"盘后","latestPrice":155.75,"preClose":155.75,"latestTime":"19:59 EDT","volume":482070,"amount":75083193.8572,"timestamp":1696031942370},"volumeRatio":1.1092139560852312},"requestUrl":"/m/hq/s/JNJ","defaultTab":"news","newsList":[{"id":"2370771782","title":"强生(JNJ)的肺癌治疗组合在后期研究中取得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2370771782","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2370771782?lang=zh_cn&edition=full","pubTime":"2023-09-28 20:36","pubTimestamp":1695904568,"startTime":"0","endTime":"0","summary":"金吾财讯 | 强生(JNJ)公司周四表示，其癌症治疗组合达到了一项后期研究的主要目标，该研究测试了该组合对一种肺癌患者的治疗作用。该制药商表示，对研究数据的中期分析显示，与阿斯利康的癌症药物奥西替尼相比，“有利于”其抗体治疗Rybrevant和实验药物lazertinib的组合的趋势。强生表示，计划为即将召开的科学会议提交数据，包括有关该研究某些次要目标的更多细节。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=13a3667a45376493ec48f22eb35715ea","is_publish_highlight":false},{"id":"2370196752","title":"【环球财经】强生将在哥斯达黎加建医疗科技新厂","url":"https://stock-news.laohu8.com/highlight/detail?id=2370196752","media":"新华财经","top":-1,"share":"https://www.laohu8.com/m/news/2370196752?lang=zh_cn&edition=full","pubTime":"2023-09-26 07:28","pubTimestamp":1695684483,"startTime":"0","endTime":"0","summary":"新华财经圣何塞9月25日电 美国跨国公司巨头强生25日宣布其医疗科技业务部门将在哥斯达黎加大都市区边缘建设一座大型医疗器械制造厂，这将是强生医疗科技在美国以外有史以来最大的投资。强生在声明中表示，新厂设施将提高强生医疗科技的制造能力，提高供应链效率和弹性，帮助开发新技术，并扩大其现有产能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202309260728058403e440&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202309260728058403e440&s=b","is_publish_highlight":false},{"id":"2368151247","title":"东星医疗(301290.SZ)：在吻合器领域目前国外主要竞争对手为强生与美敦力","url":"https://stock-news.laohu8.com/highlight/detail?id=2368151247","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2368151247?lang=zh_cn&edition=full","pubTime":"2023-09-20 13:02","pubTimestamp":1695186138,"startTime":"0","endTime":"0","summary":"格隆汇9月20日丨东星医疗(301290.SZ)在投资者互动平台表示，公司主要产品为吻合器、穿刺器、手术灯、手术床、吊桥吊塔。在吻合器领域，目前公司国外主要竞争对手为强生与美敦力，国内竞争对手主要包括瑞奇外科、法兰克曼、派尔特、天臣医疗等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230920130220825a1ea5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230920130220825a1ea5&s=b","is_publish_highlight":false},{"id":"2367616689","title":"“杨森”，再见","url":"https://stock-news.laohu8.com/highlight/detail?id=2367616689","media":"健识局","top":-1,"share":"https://www.laohu8.com/m/news/2367616689?lang=zh_cn&edition=full","pubTime":"2023-09-15 19:39","pubTimestamp":1694777945,"startTime":"0","endTime":"0","summary":"“杨森将成为光辉的历史”。从巅峰到“弃子”加入强生后，强生红和杨森蓝一直是业内一段“佳话”。杨森是第一批进入中国的跨国医药企业，是强生在中国的一张重要“名片”。这家公司，就是国人熟知的大名鼎鼎的“西安杨森”。今年以来，杨森已经剔除了7个传染病项目，其中大多数是治疗乙肝的。如今强生正式官宣，药企名录不再有“杨森”。如今更是直接抹去“杨森”品牌，上演“釜底抽薪式”调整。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230915193959824d31ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230915193959824d31ea&s=b","is_publish_highlight":false},{"id":"2367246697","title":"强生旗下制药业务杨森将更名","url":"https://stock-news.laohu8.com/highlight/detail?id=2367246697","media":"医谷","top":-1,"share":"https://www.laohu8.com/m/news/2367246697?lang=zh_cn&edition=full","pubTime":"2023-09-15 17:40","pubTimestamp":1694770801,"startTime":"0","endTime":"0","summary":"9月14日，强生宣布更新品牌，将旗下医疗科技和制药两大业务整合至至强生名下，以此将该两个细分市场与强生品牌建立更紧密的联系。其中，制药部门杨森将更名为强生创新制药，医疗科技部门则保持不变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023091517492183e5c1a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023091517492183e5c1a8&s=b","is_publish_highlight":false},{"id":"2367989136","title":"强生宣布焕新品牌，整合医疗科技与制药业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2367989136","media":"DoNews","top":-1,"share":"https://www.laohu8.com/m/news/2367989136?lang=zh_cn&edition=full","pubTime":"2023-09-15 14:54","pubTimestamp":1694760886,"startTime":"0","endTime":"0","summary":"DoNews9月15日消息，14日，强生宣布品牌焕新，将旗下医疗科技和制药两大业务整合至强生 名下，彰显公司在医疗健康领域的跨业务综合实力，持续促进医疗健康创新，解决最严峻的健康挑战，推动全球健康事业发展。未来，强生公司的两大业务将更紧密地联结在强生品牌下，公司制药业务杨森将更名为强生创新制药，强生医疗科技则保持不变。这一全新的品牌色调也传达出强生快速响应健康挑战的能力，彰显公司与时俱进、持续引领行业发展的雄心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230915145452824c781d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230915145452824c781d&s=b","is_publish_highlight":false},{"id":"2367661952","title":"所售感冒药关键成分无效 宝洁(PG.US)、强生(JNJ.US)等被告上法庭","url":"https://stock-news.laohu8.com/highlight/detail?id=2367661952","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2367661952?lang=zh_cn&edition=full","pubTime":"2023-09-15 12:06","pubTimestamp":1694750782,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宝洁、强生、沃尔格林-联合博姿在佛罗里达州被提起集体诉讼。该诉讼称，这些公司销售的非处方感冒药中使用了无效的苯肾上腺素，但消费者被误导了。强生的前消费者健康部门Kenvue销售Sudafed和Benadryl，而宝洁生产DayQuil和NyQuil。这些药品含有苯肾上腺素。9月12日，美国FDA顾问小组一致认为感冒药中的关键成分苯肾上腺素缺乏疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/995239.html","is_publish_highlight":false},{"id":"2367633991","title":"强生宣布整合医疗科技和制药业务，旗下杨森将更名为强生创新制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2367633991","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2367633991?lang=zh_cn&edition=full","pubTime":"2023-09-14 22:36","pubTimestamp":1694702161,"startTime":"0","endTime":"0","summary":"9月14日，强生宣布品牌更新，将旗下医疗科技和制药两大业务整合至强生（Johnson & Johnson）名下。未来，强生公司的两大业务将更紧密地联结在强生品牌下，公司制药业务杨森将更名为强生创新制药（Johnson & Johnson Innovative Medicine），强生医疗科技（Johnson & Johnson MedTech）则保持不变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023091422360182f3b9a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023091422360182f3b9a5&s=b","is_publish_highlight":false},{"id":"2367651386","title":"洁雅股份(301108.SZ)：面膜系列产品主要客户有欧莱雅集团、强生公司、Woolworths、伽蓝集团等","url":"https://stock-news.laohu8.com/highlight/detail?id=2367651386","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2367651386?lang=zh_cn&edition=full","pubTime":"2023-09-13 17:55","pubTimestamp":1694598954,"startTime":"0","endTime":"0","summary":"格隆汇9月13日丨洁雅股份(301108.SZ)于2023年9月12日参加投资者关系活动，就“公司面膜系列产品主要客户有哪些？上半年有没有推出面膜新品？”，公司回复称，公司面膜系列产品主要客户有欧莱雅集团、强生公司、Woolworths、伽蓝集团等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023091317560282462be6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023091317560282462be6&s=b","is_publish_highlight":false},{"id":"2365882316","title":"访强生消费者健康中国总裁：深耕中国，以高质量引领个人健康管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2365882316","media":"中国新闻网","top":-1,"share":"https://www.laohu8.com/m/news/2365882316?lang=zh_cn&edition=full","pubTime":"2023-09-06 18:35","pubTimestamp":1693996531,"startTime":"0","endTime":"0","summary":"据其介绍，研发中心以外，强生消费者健康在中国还建立了四个工厂和十个物流中心，并持续投资扩大产能、深化本土供应链合作伙伴关系，致力于以深谙本土患者与消费者需求的产品和高效协同、富有韧性的供应链保障中国大众的健康福祉。在中国，挖掘消费市场外，强生消费者健康也在积极融入绿色转型。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023090618365083c7d892&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023090618365083c7d892&s=b","is_publish_highlight":false},{"id":"2363505642","title":"强生预计分拆Kenvue将带来200亿美元的收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2363505642","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2363505642?lang=zh_cn&edition=full","pubTime":"2023-08-31 14:36","pubTimestamp":1693463766,"startTime":"0","endTime":"0","summary":"强生预期，完成分拆旗下消费者健护产品业务Kenvue后，今年的盈利增长幅度将达到双位数。公司预计今年经调整每股盈利10至10.1美元，同比增长约12.5%。消费者健护业务Kenvue不再列为持续经营业务，将在第三季将把分拆录得的200亿美元收益列帐。强生CFO表示，分拆有助集团及Kenvue专注发展自身核心业务，以争取更成功地扩充业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=36daabd4ad2a966b1b696b3af0024346","is_publish_highlight":false},{"id":"2363038174","title":"彻底分离Kenvue(KVUE.US)后 强生(JNJ.US)更新业绩展望 股息维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=2363038174","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2363038174?lang=zh_cn&edition=full","pubTime":"2023-08-30 20:29","pubTimestamp":1693398580,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，强生公司周三美股盘前公布了调整后的财务报告和经过修订后的全年业绩预期，以反映这家医疗科技兼医药保健巨头最近从其业务部门中分拆出来的提供消费者健康产品和服务的Kenvue公司。此前一项重要决议于8月23日宣布，此前该公司决定用Kenvue股票换取强生普通股。强生计划在2023年第三季度报告与Kenvue分离相关的约200亿美元资产收益，并计划将其消费者部门带来的财务数据作为已终止业务的一部分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/988168.html","is_publish_highlight":false},{"id":"2363042268","title":"面临仿制药竞争 强生(JNJ.US)默沙东(MRK.US)抗议“美版”医保谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=2363042268","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2363042268?lang=zh_cn&edition=full","pubTime":"2023-08-30 16:26","pubTimestamp":1693383971,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在美国首次进行价格谈判的10种重磅药物中，强生公司的Stelara、默沙东的Januvia预计在2026年谈判价格生效时将面临廉价竞争。面临低成本同类产品竞争的药物本应免于与美国医疗保险计划的谈判。强生在一份声明中表示，该政策“价格控制条款将限制医疗创新，限制患者的获取和选择，并对整体护理质量产生负面影响”。默沙东警告说，这将扼杀研究，并为寻求治愈的患者带来“潜在的破坏性后果”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308301627248215e4a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308301627248215e4a6&s=b","is_publish_highlight":false},{"id":"2362180607","title":"砍管线自救，强生、拜耳等多家知名药企大幅裁员，会否波及中国市场？","url":"https://stock-news.laohu8.com/highlight/detail?id=2362180607","media":"华夏时报","top":-1,"share":"https://www.laohu8.com/m/news/2362180607?lang=zh_cn&edition=full","pubTime":"2023-08-26 17:28","pubTimestamp":1693042114,"startTime":"0","endTime":"0","summary":"本报（chinatimes.net.cn）记者于娜 北京报道因为涉及的医药企业中不乏知名巨头，让这一轮的“裁员潮”引发关注。近日，美国癌症免疫疗法公司Agenus 宣布计划裁员25%，并大幅缩减癌症药物研究。就在同一天，强生旗下的杨森制药打算关闭位于荷兰莱顿的传染病和疫苗部门，而两个部门重组刚过半年时间。截至8月，强生、辉瑞、...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OyhxzkmOm03xB0FsqtwVq6IjsfBX17PgPN1u9qBjGWYsYAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OyhxzkmOm03xB0FsqtwVq6IjsfBX17PgPN1u9qBjGWYsYAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20230826A05WGE00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20230826A05WGE00","is_publish_highlight":false},{"id":"2362591031","title":"强生完成消费者健康业务拆分，Kenvue将独立运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2362591031","media":"鞭牛士","top":-1,"share":"https://www.laohu8.com/m/news/2362591031?lang=zh_cn&edition=full","pubTime":"2023-08-25 13:17","pubTimestamp":1692940674,"startTime":"0","endTime":"0","summary":"鞭牛士 8月25日消息，近日强生集团宣布顺利完成分拆Johnson & Johnson和Kenvue的换股要约。即日起，Kenvue将完全独立运营。据悉，此次分拆重组计划预计在2023年内完成，届时Kenvue将作为一家消费者健康公司独立运营。强生公司成立于1886年，是全球最具综合性、业务分布范围广的医疗健康企业之一，业务涉及医疗器材、制药和消费品三大领域。总部位于美国新泽西州新布仑兹维克市，在全球60个国家地区拥有260多家运营公司，全球员工超过13万人，2020年全球营收达826亿美元，全球研发投入达122亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308251319098434cfb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308251319098434cfb7&s=b","is_publish_highlight":false},{"id":"2361696532","title":"巨头关闭疫苗部门？多家知名药企大幅裁员","url":"https://stock-news.laohu8.com/highlight/detail?id=2361696532","media":"虎嗅网","top":-1,"share":"https://www.laohu8.com/m/news/2361696532?lang=zh_cn&edition=full","pubTime":"2023-08-24 21:51","pubTimestamp":1692885060,"startTime":"0","endTime":"0","summary":"就在同一天，有报道称，强生旗下的杨森制药打算关闭位于荷兰莱顿的传染病和疫苗部门，这距离两个部门重组不过半年多时间。巨头也“受挫”今年上半年，强生的新冠疫苗收入下滑了近50%，传染病部门也就成为杨森制药唯一出现两位数收入下滑的板块。这可能是强生下定决心“关闭”传染病和疫苗部门的重要原因。2022年底，强生悄悄关闭了唯一可用于生产新冠疫苗的工厂，正是此次传出裁员传闻的荷兰莱顿杨森的工厂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308242155058432ccd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308242155058432ccd1&s=b","is_publish_highlight":false},{"id":"2361952333","title":"强生宣布顺利完成消费者健康业务的分拆","url":"https://stock-news.laohu8.com/highlight/detail?id=2361952333","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2361952333?lang=zh_cn&edition=full","pubTime":"2023-08-24 20:05","pubTimestamp":1692878700,"startTime":"0","endTime":"0","summary":"美国新泽西州新不伦瑞克2023年8月24日 /PRNewswire/ -- 2023年8月23日，强生公司正式宣布了顺利完成分拆Johnson & Johnson 和 Kenvue 的换股要约。根据要约，强生公司已接受190,955,436股强生公司普通股，以交换获得1,533,830,450股Kenvue普通股。由于换股要约获得超额认购，基于投标股数量，强生公司仅按比例接受了有效投标但未被有效撤回的强生公司普通股的一部分。换股要约完成后，强生公司将继续持有占Kenvue普通股总量约9.5%的股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4192295_ZH92295_1","is_publish_highlight":false},{"id":"2361512419","title":"强生完成消费者健康业务分拆","url":"https://stock-news.laohu8.com/highlight/detail?id=2361512419","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2361512419?lang=zh_cn&edition=full","pubTime":"2023-08-24 19:27","pubTimestamp":1692876434,"startTime":"0","endTime":"0","summary":"强生中国微信公众号8月24日消息，8月23日，强生公司正式宣布了顺利完成分拆Johnson&Johnson和Kenvue的换股要约。即日起，Kenvue将完全独立运营。据介绍，强生公司将继续持有占Kenvue普通股总量约9.5%的股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023082419271482edbdda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023082419271482edbdda&s=b","is_publish_highlight":false},{"id":"2361639667","title":"东星医疗：公司吻合器产品价格低于强生、美敦力等国外品牌同类产品，具有一定的价格优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2361639667","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2361639667?lang=zh_cn&edition=full","pubTime":"2023-08-22 14:39","pubTimestamp":1692686348,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：穿刺器产品是做羊水穿刺的么？新一代产品是否可以降低穿刺的风险？公司的吻合器产品与目前主流的国外品牌同款同质的情况下能降低多少价格？东星医疗（301290.SZ）8月22日在投资者互动平台表示，穿刺器是指腹腔镜用穿刺器，用于穿透腹壁全层，配合微创设备，为腹腔微创手术提供手术器械进入腹腔的通道，主要应用于腹腔手术等外科手术中。公司吻合器产品价格低于强生、美敦力等国外品牌同类产品，具有一定的价格优势。(记者 蔡鼎)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230822143956842b739e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230822143956842b739e&s=b","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.0487},{"period":"3month","weight":-0.059},{"period":"6month","weight":0.0048},{"period":"1year","weight":-0.0534},{"period":"ytd","weight":-0.1183}],"websiteUrl":"http://www.jnj.com","compareEarnings":[{"period":"1week","weight":-0.0068},{"period":"1month","weight":-0.0522},{"period":"3month","weight":-0.0356},{"period":"6month","weight":0.0442},{"period":"1year","weight":0.1783},{"period":"ytd","weight":0.1178}],"name":"强生","description":"强生公司于1887年在新泽西州成立。强生公司及其子公司在全球拥有大约152,700名员工，从事医疗保健领域的广泛产品的研发，生产和销售。强生公司是一家控股公司，在全球几乎所有国家/地区都有260多家运营公司开展业务。公司的主要重点是与人类健康和福祉相关的产品。强生执行委员会是主要的管理团队，负责公司的战略运营和资源分配。委员会负责监督和协调公司三个业务部门的活动：消费者，制药和医疗设备。","yearOnYearQuotes":[{"month":1,"riseRate":0.511628,"avgChangeRate":0.000114},{"month":2,"riseRate":0.488372,"avgChangeRate":-0.006161},{"month":3,"riseRate":0.604651,"avgChangeRate":0.017757},{"month":4,"riseRate":0.659091,"avgChangeRate":0.037113},{"month":5,"riseRate":0.477273,"avgChangeRate":-0.027248},{"month":6,"riseRate":0.522727,"avgChangeRate":0.006309},{"month":7,"riseRate":0.590909,"avgChangeRate":0.010998},{"month":8,"riseRate":0.5,"avgChangeRate":0.002512},{"month":9,"riseRate":0.5,"avgChangeRate":0.003139},{"month":10,"riseRate":0.72093,"avgChangeRate":0.023654},{"month":11,"riseRate":0.604651,"avgChangeRate":0.016412},{"month":12,"riseRate":0.651163,"avgChangeRate":0.014358}],"exchange":"NYSE","nameEN":"Johnson & Johnson","compareStock":{"symbol":"SPY","name":"标普500ETF"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.17.2","shortVersion":"4.17.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"强生(JNJ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供强生(JNJ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"强生,JNJ,强生股票,强生股票老虎,强生股票老虎国际,强生行情,强生股票行情,强生股价,强生股市,强生股票价格,强生股票交易,强生股票购买,强生股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"强生(JNJ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供强生(JNJ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}